cycD1/CCND1 Cancer Research Results

cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
Scientific Papers found: Click to Expand⟱
12- CUR,    Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells
- in-vitro, MB, DAOY
HH↓, Shh↓, Gli1↓, PTCH1↓, cMyc↓, n-MYC↓, cycD1/CCND1↓, Bcl-2↓, NF-kB↓, Akt↓, β-catenin/ZEB1↓, survivin↓, Apoptosis↑, ChemoSen↑, RadioS↑, eff↑,
9- CUR,    Curcumin Suppresses Malignant Glioma Cells Growth and Induces Apoptosis by Inhibition of SHH/GLI1 Signaling Pathway in Vitro and Vivo
- vitro+vivo, MG, U87MG - vitro+vivo, MG, T98G
HH↓, Shh↓, Gli1↓, cycD1/CCND1↓, Bcl-2↓, FOXM1↓, Bax:Bcl2↑, TumCP↓, TumCMig↓, Apoptosis↑, TumVol↑, TumCCA↑, Casp3↑, OS↑,
165- CUR,    Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
AR↓, β-catenin/ZEB1↓, p‑Akt↓, GSK‐3β↓, p‑β-catenin/ZEB1↑, cycD1/CCND1↓, cMyc↓, chemoPv↑, TumCP↓,
170- CUR,    Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
- vitro+vivo, Pca, PC3
TRAILR↑, BAX↑, P21↑, p27↑, NF-kB↓, cycD1/CCND1↓, VEGF↓, uPA↓, MMP2↓, MMP9↓, Bcl-2↓, Bcl-xL↓,
6246- Cyc,    Cyclopamine is a novel Hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
HH↓, TumCP↓, TumCCA↓, TumCI↓, NF-kB↓, MMP2↓, MMP9↓, ERα/ESR1↓, cycD1/CCND1↓,
6247- Cyc,    Sonic Hedgehog Pathway Contributes to Gastric Cancer Cell Growth and Proliferation
- vitro+vivo, GC, MKN45
Shh↓, TumCP↓, TumCCA↓, Apoptosis↓, TumCG↓, cycD1/CCND1↓,
1183- DHA,    Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo
- in-vitro, BC, 4T1 - in-vitro, BC, MCF7 - in-vivo, BC, NA
TumCG↓, TumCCA↑, β-catenin/ZEB1↓, TCF↓, LEF1↓, cMyc↓, cycD1/CCND1↓, Wnt/(β-catenin)↓, TumMeta↓,
2270- dietMet,    Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice
- in-vivo, Var, NA
Weight↓, TumVol↓, P21↑, p27↑, *adiP↑, *glucose↓, *IGF-1↓, *FGF21↑, *OS↑, Ki-67↓, Casp3↑, cycD1/CCND1↓,
6266- DL,    Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer
- Trial, BC, NA
chemoPv↑, cycD1/CCND1↓, IGF-1↑, TumCCA↑, TumCP↓,
6267- DL,    Effect of d-limonene and its derivatives on breast cancer in human trials: a scoping review and narrative synthesis
- Review, BC, NA
*toxicity↓, cycD1/CCND1↓, TumCP↓, other↑,
6281- DL,    Applications of Limonene in Neoplasms and Non-Neoplastic Diseases
- Review, Var, NA - Review, AD, NA - Review, Diabetic, NA
*antiOx↑, AntiTum↑, *AntiDiabetic↑, *neuroP↑, *GastroP↑, *ROS↓, *toxicity↓, *BioAv↑, ChemoSen↑, BAX↑, P53↓, Bcl-2↓, iNOS↓, COX2↓, eff↑, ROS↑, TumCCA↑, cycD1/CCND1↓, CycB/CCNB1↓, TumCMig↓, *lipid-P↓, *GSH↑, *SOD↑, *GPx↑, *hepatoP↑, *glucose↓, *AGEs↓, *Obesity↓, *Aβ↓, *AChE↓,
6279- DL,    Human breast tissue disposition and bioactivity of limonene in women with early stage breast cancer
- Trial, BC, NA
chemoPv↑, cycD1/CCND1↓,
6276- DL,  Tam,    Combination of tamoxifen and D-limonene enhances therapeutic efficacy in breast cancer cells
- in-vitro, BC, MCF7
TumCG↓, tumCV↓, TumCCA↑, cycD1/CCND1↓, CycB/CCNB1↓, Apoptosis↑,
6363- DRE,    Therapeutic Potential of Dandelion (Taraxacum officinale) Root Extract in Colon Cancer: A Comprehensive Review
- in-vitro, CRC, NA
Apoptosis↑, *Inflam↓, TLR4↓, NF-kB↓, *GutMicro↑, mtDam↑, *ROS↓, Casp1↑, TNF-α↑, Bcl-2↓, PARP↓, MMP↓, Cyt‑c↓, Casp3↑, TumVol↓, COX2↓, iNOS↓, ROS↑, selectivity↑, TumCMig↓, TumCI↓, ER Stress↑, PERK↑, eIF2α↑, ATF4↑, CHOP↑, TumCCA↑, cycD1/CCND1↓, P21↓, P53↑, BioAv↝, Half-Life↝,
5012- DSF,  Cu,    Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems
ROS↑, ALDH↓, TumCP↓, CSCs↓, angioG↓, TumMeta↓, DNAdam↑, Proteasome↓, SOD1↓, GSR↓, ox-GSSG↑, GSH/GSSG↓, MMP↓, Akt↓, cycD1/CCND1↓, NF-kB↓, CSCs↓, MAPK↓, angioG↓, DrugR↓, EMT↓, Vim↓, BioAv↑, eff↑,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
1606- EA,    Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells
- in-vitro, Colon, HCT15
TumCP↓, cycD1/CCND1↓, Apoptosis↑, PI3K↓, Akt↓, ROS↑, Casp3↑, Cyt‑c↑, Bcl-2↓, TumCCA↑, Dose∅, ALP↓, LDH↓, PCNA↓, P53↑, Bax:Bcl2↑,
1613- EA,    Ellagitannins in Cancer Chemoprevention and Therapy
- Review, Var, NA
ROS↑, angioG↓, ChemoSen↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, CDK2↓, CDK4↓, CDK6↓, cycD1/CCND1↓, cycE1↓, TumCG↓, VEGF↓, Hif1a↓, eff↑, COX2↓, TumCCA↑, selectivity↑, Wnt/(β-catenin)↓, *toxicity∅,
27- EA,    Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice
- in-vivo, PC, PANC1
HH↓, Gli1↓, GLI2↓, CDK1/2/5/9↓, p‑Akt↓, NOTCH1↓, Shh↓, Snail↓, E-cadherin↑, NOTCH3↓, HEY1↓, TumCG↓, TumCP↓, Casp3↑, cl‑PARP↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, CDK6↓, BAX↑, COX2↓, Hif1a↓, VEGF↓, VEGFR2↓, IL6↓, IL8↓, MMP2↓, MMP9↓, NA↓,
1057- EDM,    Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion
NF-kB↓, TNF-α↓, COX2↓, cycD1/CCND1↓, cMyc↓, MMP9↓, ICAM-1↓, MDR1↓, XIAP↓, Bcl-2↓, Bcl-xL↓, IAP1↓, IAP2↓, cFLIP↓, Bfl-1↓,
1303- EGCG,    (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation
- in-vitro, EC, NA
TumCP↓, ER-α36↓, cycD1/CCND1↓, ERK↑, Jun↓, BAX↑, Bcl-2↓, cl‑Casp3↑, ROS↑, p38↑,
3228- EGCG,    Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids
*cycD1/CCND1↓, *COL1A1↓, *ACTA2↓, *α-SMA↓,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
5225- EMD,    Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
STAT3↓, Akt↓, cSrc↓, JAK1↓, JAK2↓, SHP1↑, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCP↓, Casp3↑, cl‑PARP↑, ChemoSen↑, XIAP↓,
6389- Eug,    Molecular Insights into the Management of Eugenol's Anticancer Action Against Colon Cancer: A Detailed Review
- Review, Colon, NA
Apoptosis↓, TumCCA↓, Inflam↓, TumMeta↓, BioAv↑, eff↓, Half-Life↓, *ROS↓, *RNS↓, *SOD↓, *Catalase↑, *GSTs↑, *MAOA↓, *neuroP↑, *DNAdam↓, Apoptosis↑, ROS↑, selectivity↑, MMP↓, Cyt‑c↓, Casp3↑, Casp9↑, TumCD↑, BAX↑, BAD↑, APAF1↑, Bcl-2↓, Bcl-xL↓, P53↑, cl‑PARP↑, TumCCA↑, cycD1/CCND1↓, CycB/CCNB1↓, CDK2↓, CDK4↓, P21↑, p27↑, NF-kB↓, COX2↓, PGE2↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, MMPs↓, EMT↓, Snail↓, Slug↓, Zeb1↓, E-cadherin↑, ChemoSen↑,
6386- Eug,    A comprehensive and systematic review on potential anticancer activities of eugenol: From pre-clinical evidence to molecular mechanisms of action
- Review, Var, NA
Apoptosis↑, TumAuto↑, TumCCA↑, Inflam↝, TumCI↓, TumMeta↓, cycD1/CCND1↓, CycB/CCNB1↓, PCNA↓, NF-kB↓, Bcl-2↓, BAX↑, AIF↑, P21↑, P53↑, ChemoSen↑,
6388- Eug,    Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review
- Review, Var, NA
Dose↝, AntiCan↑, *Inflam↓, *cardioP↑, *neuroP↑, angioG↓, TumMeta↓, *BioAv↑, *eff↑, *toxicity↝, antiNeop↑, TumCCA↑, Apoptosis↑, *antiOx↑, *lipid-P↓, *ROS↓, *SOD↑, *Catalase↑, *GSTs↑, *GPx↑, *iNOS↓, *COX2↓, *IL6↓, *TNF-α↓, *AntiArt↑, *Bacteria↓, TumAuto↑, PI3K↓, Akt↓, FOXO3↝, BAX↑, mTOR↓, NF-kB↓, P53↑, TumCG↓, CSCs↓, CD44↓, EpCAM↓, NOTCH1↓, OCT4↓, Bcl-2↓, PDK1↓, HER2/EBBR2↓, BAD↓, cycD1/CCND1↓, ROS↑, Casp3↑, selectivity↑, MMP2↓, MMP9↓, TIMP1↑, VEGF↓, VEGFR1↓, RECK↑, TIMP2↑, DNAdam↑, MMP↓, Thiols↓, PARP↑, *Pain↓, E2Fs↓, survivin↓,
6337- Eug,    Eugenol alleviated breast precancerous lesions through HER2/PI3K-AKT pathway-induced cell apoptosis and S-phase arrest
- in-vitro, BC, MCF-10AT
TumCP↓, TumCCA↑, HER2/EBBR2↓, Akt↓, PDK1↓, Bcl-2↓, NF-kB↓, BAD↓, cycD1/CCND1↓,
6340- Eug,    Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation
- in-vitro, BC, MCF7 - in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231
tumCV↓, E2Fs↓, survivin↓, NF-kB↓, cycD1/CCND1↓, P21↑, TumCP↓, Apoptosis↑, TumCI↓, angioG↓,
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,
1655- FA,    Ferulic acid inhibiting colon cancer cells at different Duke’s stages
- in-vitro, Colon, SW480 - in-vitro, Colon, Caco-2 - in-vitro, Colon, HCT116
TumCP↓, TumCMig↓, TumCCA↑, Apoptosis↑, ATM↑, Chk2↑, ATR↑, CHK1↑, CK2↓, cycA1/CCNA1↑, CDK4↓, CDK6↓, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑,
2847- FIS,    Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells
- in-vitro, CCA, NA
tumCV↓, ChemoSen↑, TumCMig↓, ROS↑, TumCI↓, angioG↓, CDK2↓, PI3K↓, Akt↓, mTOR↓, EGFR↓, Casp↑, mTORC1↓, mTORC2↑, cycD1/CCND1↓, cycE/CCNE↓, MMP2↓, MMP9↓, ER Stress↑, Ca+2↑, eff↓,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2↓, IAP2↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
2828- FIS,    Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review
- Review, Var, NA
*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP↑, ROS↑, cMyc↓, cardioP↑,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
2843- FIS,    Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
- Review, Var, NA
NRF2↑, Keap1↓, ChemoSen↑, BioAv↓, Cyt‑c↑, Casp3↑, Casp9↑, BAX↑, tumCV↓, Mcl-1↓, cl‑PARP↑, IGF-1↓, Akt↓, CDK6↓, TumCCA↑, P53?, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, MMP2↓, MMP9↓, MMP1↓, MMP7↓, MMP3↓, VEGF↓, PI3K↓, mTOR↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, ERK↓, ROS↑, angioG↓, TNF-α↓, PGE2↓, iNOS↓, NO↓, IL6↓, HSP70/HSPA5↝, HSP27↝,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
1086- GA,    Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation
- in-vitro, AML, K562
tumCV↓, TumCCA↑, P21↑, p27↑, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Cyt‑c↑, cl‑PARP↓, DNAdam↑, Casp3↑, FASN↓, Casp8↑,
1065- GA,    Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression
- vitro+vivo, Pca, NA
tumCV↓, MMP↓, DNAdam↑, HDAC1↓, HDAC2↓, PCNA↓, cycD1/CCND1↓, cycE1↓, P21↑, TumVol↓,
5150- GamB,    Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway
- in-vitro, CLL, KBM-5 - in-vitro, Nor, HEK293
Apoptosis↑, ChemoSen↑, IAP1↓, IAP2↓, Bcl-2↓, Bcl-xL↓, TRAF1↓, cycD1/CCND1↓, cMyc↓, COX2↓, MMP9↓, angioG↓, VEGF↓, NF-kB↓, eff↓,
804- GAR,    Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest
- in-vitro, EC, HEC1B - in-vitro, EC, ISH
TumCP↓, TumCCA↑, P53↑, P21↑, CDK2↓, CDK4↓, cycD1/CCND1↓, CycB/CCNB1↓, p‑cJun↑,
803- GAR,    Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer
- in-vitro, Lung, H1299 - in-vitro, Lung, H460
TumCP↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↑, CDK6↑, P21↑, p27↑, ERK↓, MAPK↓,
802- GAR,    Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway
- in-vitro, GC, HGC27
TumCP↓, TumCI↓, Apoptosis↑, PI3K/Akt↓, Akt↓, p‑mTOR↓, cycD1/CCND1↓, MMP2↓, MMP9↓, BAX↑, Bcl-2↓,
801- GAR,  Cisplatin,    Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers
- in-vivo, HNSCC, NA
Apoptosis↑, cycD1/CCND1↓, Bcl-2↓, survivin↓, VEGF↓, TumCG↓, Ki-67↓, CD31↓,
798- GAR,    Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol
- in-vitro, BC, MCF7
TumCP↓, TumCCA↑, Apoptosis↑, ac‑H3↑, ac‑H4∅, NF-kB↓, ac‑p65↑, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓,
826- GAR,    Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
- vitro+vivo, HCC, HepG2 - vitro+vivo, Liver, HUH7
STAT3↓, TumCP↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCCA↑, TumVol↓,

Showing Research Papers: 101 to 150 of 288
Prev Page 3 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 288

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   GSH↓, 1,   GSH/GSSG↓, 1,   GSR↓, 1,   ox-GSSG↑, 1,   GSTs↓, 1,   GSTs↑, 1,   HO-1↓, 2,   HO-1↑, 1,   HO-2↓, 1,   Keap1↓, 1,   lipid-P↓, 1,   MAD↓, 1,   NRF2↓, 1,   NRF2↑, 2,   PYCR1↓, 1,   ROS↓, 4,   ROS↑, 20,   mt-ROS↑, 1,   SOD↓, 1,   SOD1↓, 1,   Thiols↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 4,   Bfl-1↓, 1,   CDC2↓, 2,   CDC25↓, 3,   EGF↓, 2,   FGFR1↓, 1,   MEK↓, 1,   MMP↓, 13,   mtDam↑, 2,   OCR↓, 1,   XIAP↓, 5,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 2,   AMPK↑, 4,   CAIX↓, 1,   cMyc↓, 8,   ECAR↝, 1,   FASN↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   lactateProd↓, 1,   LDH↓, 3,   PCK1↓, 1,   PDH↝, 1,   PDK1?, 2,   PDK1↓, 2,   PI3K/Akt↓, 1,   PKM2↓, 1,   cl‑PPARα↓, 1,   SIRT1↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 18,   Akt↑, 1,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↓, 2,   Apoptosis↑, 18,   BAD↓, 2,   BAD↑, 3,   Bak↑, 2,   BAX↑, 17,   BAX⇅, 1,   Bax:Bcl2↑, 5,   Bcl-2↓, 28,   Bcl-xL↓, 10,   BID↑, 1,   BIM↑, 3,   Casp↑, 4,   Casp1↑, 1,   Casp3↑, 19,   cl‑Casp3↑, 2,   Casp8↑, 3,   cl‑Casp8↑, 1,   Casp9↑, 6,   cl‑Casp9↑, 2,   cFLIP↓, 1,   Chk2↑, 2,   CK2↓, 1,   Cyt‑c↓, 2,   Cyt‑c↑, 13,   Diablo↑, 7,   DR4↑, 2,   DR5↑, 4,   Fas↑, 2,   HEY1↓, 1,   IAP1↓, 2,   IAP2↓, 3,   iNOS↓, 4,   JNK↓, 1,   JNK↑, 1,   MAPK↓, 7,   Mcl-1↓, 8,   MDM2↓, 1,   MDM2↑, 1,   Myc↓, 2,   NOXA↑, 1,   p27↑, 8,   p38↓, 1,   p38↑, 1,   p‑p38↓, 1,   Proteasome↓, 1,   PUMA↑, 1,   survivin↓, 10,   Telomerase↓, 2,   TRAIL↑, 1,   TRAILR↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,   HER2/EBBR2↓, 3,   p70S6↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 5,   p‑cJun↑, 1,   p‑H3↓, 1,   ac‑H3↑, 1,   ac‑H4∅, 1,   HATs↓, 1,   other↑, 1,   pRB↑, 1,   tumCV↓, 7,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 4,   eIF2α↑, 1,   ER Stress↑, 6,   GRP78/BiP↑, 3,   HSF1↓, 1,   HSP27↓, 2,   HSP27↝, 1,   HSP70/HSPA5↓, 3,   HSP70/HSPA5↝, 1,   IRE1↑, 3,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3II↑, 2,   LC3s↑, 1,   p62↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 2,   ATR↑, 1,   CHK1↑, 2,   DNAdam↓, 1,   DNAdam↑, 9,   DNMTs↓, 1,   p16↑, 1,   P53?, 1,   P53↓, 1,   P53↑, 14,   PARP↓, 1,   PARP↑, 1,   cl‑PARP↓, 1,   cl‑PARP↑, 12,   PCNA↓, 7,   SIRT6↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK1/2/5/9↓, 1,   CDK2↓, 16,   CDK2↑, 1,   CDK4↓, 15,   cycA1/CCNA1↓, 2,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 5,   cycD1/CCND1↓, 49,   CycD3↓, 1,   cycE/CCNE↓, 9,   cycE/CCNE↑, 1,   cycE1↓, 2,   E2Fs↓, 2,   P21↓, 1,   P21↑, 17,   p‑RB1↓, 1,   Securin↓, 1,   TumCCA↓, 3,   TumCCA↑, 27,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD44↓, 1,   CDK8↓, 1,   cFos↓, 5,   CIP2A↓, 1,   CSCs↓, 3,   EMT↓, 8,   EpCAM↓, 1,   ERK↓, 3,   ERK↑, 2,   p‑ERK↓, 2,   FOXM1↓, 1,   FOXO↑, 1,   FOXO3↝, 1,   Gli1↓, 3,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC2↓, 1,   HH↓, 4,   IGF-1↓, 1,   IGF-1↑, 1,   Jun↓, 1,   miR-34a↑, 1,   mTOR↓, 11,   p‑mTOR↓, 1,   mTORC1↓, 5,   mTORC2↓, 3,   mTORC2↑, 1,   n-MYC↓, 1,   NOTCH↓, 3,   NOTCH1↓, 2,   NOTCH3↓, 1,   OCT4↓, 1,   PI3K↓, 11,   PTCH1↓, 1,   PTEN↑, 1,   RAS↓, 1,   Shh↓, 4,   SHP1↑, 1,   STAT3↓, 4,   p‑STAT3↓, 1,   STAT6↓, 1,   TCF↓, 1,   TCF↑, 1,   TCF-4↓, 2,   TOP1↓, 1,   TOP2↓, 1,   TumCG↓, 8,   Wnt↓, 6,   Wnt/(β-catenin)↓, 3,  

Migration(tgid=13) ⓘ

AP-1↓, 3,   Ca+2↑, 4,   Ca+2↝, 1,   CD31↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 7,   ER-α36↓, 1,   FAK↓, 1,   p‑FAK↓, 1,   Fibronectin↓, 2,   GLI2↓, 1,   Ki-67↓, 5,   LEF1↓, 1,   MET↓, 1,   MMP1↓, 2,   MMP13↓, 1,   MMP2↓, 15,   MMP3↓, 2,   MMP7↓, 5,   MMP9↓, 17,   MMPs↓, 2,   N-cadherin↓, 3,   PDGF↓, 1,   PKCδ↓, 2,   RECK↑, 1,   Rho↓, 1,   Slug↓, 1,   SMAD3↓, 1,   Snail↓, 6,   TGF-β↓, 2,   TGF-β↑, 1,   TIMP1↑, 1,   TIMP2↑, 2,   TumCA↓, 1,   TumCI↓, 9,   TumCMig↓, 6,   TumCMig↑, 1,   TumCP↓, 21,   TumMeta↓, 8,   Twist↓, 3,   uPA↓, 9,   VEGFR1↓, 1,   Vim↓, 6,   Zeb1↓, 2,   β-catenin/ZEB1↓, 8,   p‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 13,   ATF4↓, 1,   ATF4↑, 4,   EGFR↓, 8,   Endoglin↑, 1,   eNOS↓, 1,   Hif1a↓, 5,   NO↓, 1,   NO↑, 1,   VEGF↓, 14,   VEGFR2↓, 3,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   NHE1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2↓, 16,   ICAM-1↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 3,   Inflam↝, 1,   JAK↓, 1,   JAK1↓, 2,   JAK2↓, 2,   NF-kB↓, 25,   NF-kB↑, 1,   p65↓, 1,   ac‑p65↑, 1,   PD-1↓, 1,   PD-L1↓, 1,   PGE2↓, 5,   TLR4↓, 1,   TNF-α↓, 4,   TNF-α↑, 1,   TRAF1↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   CDK6↓, 12,   CDK6↑, 1,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 15,   Dose↑, 1,   Dose↝, 3,   Dose∅, 2,   DrugR↓, 1,   eff↓, 3,   eff↑, 14,   Half-Life↓, 2,   Half-Life↝, 2,   MDR1↓, 1,   RadioS↑, 7,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

ALP↓, 1,   AR↓, 2,   EGFR↓, 8,   ERα/ESR1↓, 1,   FOXM1↓, 1,   HER2/EBBR2↓, 3,   IL6↓, 2,   Ki-67↓, 5,   LDH↓, 3,   Myc↓, 2,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   antiNeop↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 3,   ChemoSideEff↓, 2,   hepatoP↑, 1,   neuroP↑, 1,   OS↑, 1,   RenoP↑, 2,   TumVol↓, 4,   TumVol↑, 1,   TumW↓, 1,   Weight↓, 1,  
Total Targets: 352

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 6,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 2,   GSTs↑, 2,   HO-1↑, 1,   lipid-P↓, 2,   NRF2↑, 2,   RNS↓, 1,   ROS↓, 5,   SOD↓, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

adiP↑, 1,   p‑cMyc↑, 1,   FGF21↑, 1,   glucose↓, 2,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   p16↓, 1,   P53↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1,   IGF-1↓, 1,  

Migration(tgid=13) ⓘ

ACTA2↓, 1,   COL1A1↓, 1,   α-SMA↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   IL6↓, 1,   Inflam↓, 5,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   MAOA↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,   Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 5,   Obesity↓, 1,   OS↑, 1,   Pain↓, 1,   toxicity↓, 2,   toxicity↝, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 54

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
20 Quercetin
19 Thymoquinone
16 Curcumin
11 Lycopene
10 Resveratrol
9 Boswellia (frankincense)
9 Fisetin
7 Berberine
7 Chrysin
6 Sulforaphane (mainly Broccoli)
6 Garcinol
6 Honokiol
5 Silver-NanoParticles
5 Artemisinin
5 Baicalein
5 D-limonene
5 Ellagic acid
5 Eugenol
5 Magnolol
5 salinomycin
5 Silymarin (Milk Thistle) silibinin
5 Shikonin
4 Apigenin (mainly Parsley)
4 Caffeic acid
4 Metformin
4 Piperlongumine
3 Cisplatin
3 Beta-Caryophyllene
3 Betulinic acid
3 Capsaicin
3 Carvacrol
3 Centella asiatica / Gotu kola → asiaticoside
3 Ursolic acid
3 EGCG (Epigallocatechin Gallate)
3 HydroxyTyrosol
3 Luteolin
3 Propolis -bee glue
3 Vitamin K2
2 Sorafenib (brand name Nexavar)
2 Astragalus
2 Allicin (mainly Garlic)
2 Anethole/trans-Anethole
2 Astaxanthin
2 Berbamine
2 Bufalin/Huachansu
2 Chemotherapy
2 Carnosic acid
2 Celastrol
2 Cucurbitacin
2 Cyclopamine
2 Ferulic acid
2 Gallic acid
2 Graviola
2 Niclosamide (Niclocide)
2 Phenethyl isothiocyanate
2 VitK3,menadione
2 Rosmarinic acid
1 2-DeoxyGlucose
1 Alpha-Lipoic-Acid
1 Andrographis
1 Gemcitabine (Gemzar)
1 Fennel Oil/Foeniculum vulgare
1 Ashwagandha(Withaferin A)
1 Radiotherapy/Radiation
1 borneol
1 Boron
1 Butyrate
1 Caffeine
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Chlorogenic acid
1 Chlorophyllin
1 Crocetin
1 Dihydrocaffeic Acid
1 Docosahexaenoic Acid
1 diet Methionine-Restricted Diet
1 tamoxifen
1 Dandelion Root
1 Disulfiram
1 Copper and Cu NanoParticles
1 Evodiamine
1 Emodin
1 Gambogic Acid
1 Germacranolide
1 Geraniol
1 Siegesbeckia glabrescens
1 Baicalin
1 Inositol
1 Ivermectin
1 lambertianic acid
1 Licorice
1 Melatonin
1 Mushroom Chaga
1 Mushroom Shiitake, AHCC
1 Myricetin
1 Naringin
1 Nimbolide
1 Orlistat
1 Plumbagin
1 Pterostilbene
1 doxorubicin
1 Paclitaxel
1 Selenite (Sodium)
1 Terpinen-4-ol / Tea Tree Oil
1 Urolithin
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:73  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page